NBIO (Nascent Biotech) FCF Margin %: 0.00% (As of Jun. 2024)


What is Nascent Biotech FCF Margin %?

Nascent Biotech NBIO +66.67% FCF Margin % is 0.00% as of Jun. 2024.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nascent Biotech's Free Cash Flow for the three months ended in Jun. 2024 was $-0.33 Mil. Nascent Biotech's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Nascent Biotech's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Nascent Biotech's current FCF Yield % is 0.00%.

The historical rank and industry rank for Nascent Biotech's FCF Margin % or its related term are showing as below:


NBIO's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Nascent Biotech FCF Margin % Related Terms

Nascent Biotech FCF Margin % Historical Data

* Premium members only.

The historical data trend for Nascent Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Biotech FCF Margin % Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
FCF Margin %
Get a 7-Day Free Trial 0.00 -131.60 41.30 0.00 0.00

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NBIO vs BTAX, PXMD, XSNX: FCF Margin % Comparison

For the Biotechnology subindustry, Nascent Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nascent Biotech FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's FCF Margin % falls into.


Nascent Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nascent Biotech's FCF Margin for the fiscal year that ended in Mar. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=-1.186/0
= %

Nascent Biotech's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-0.325/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Nascent Biotech (NBIO) has a FCF Margin % of 0.00% as of Jun. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nascent Biotech and its competitors.
Is Nascent Biotech's FCF Margin % too high?
Nascent Biotech's current FCF Margin % is 0.00%.
How does Nascent Biotech's FCF Margin % compare to BTAX and PXMD?
Nascent Biotech's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nascent Biotech and its competitors. Nascent Biotech's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Biotech stock overvalued right now?
Nascent Biotech (NBIO) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nascent Biotech (NBIO), the current FCF Margin % is 0.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Biotech Business Description

Address 631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.